{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:03:20Z","timestamp":1790697800116,"version":"4.1.0"},"reference-count":47,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Musculoskeletal"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>The idiopathic inflammatory myopathies are chronic diseases of the skeletal muscle that comprise various conditions, including dermatomyositis, polymyositis, immune-mediated necrotizing myopathy, and the antisynthetase syndrome. Although there are a number of distinguishing features, all these disorders are characterized by an immune and inflammatory response mainly directed against the muscle. Hence, therapy is geared toward curbing the autoimmune and inflammatory response. A quite wide range of medications are currently available to treat these disorders, but despite all therapeutic progress still a number of patients are unable to maintain a sustained remission. In this review article, we have marshaled a variety of potential therapeutic agents that may hold promise for the future treatment of the idiopathic inflammatory myopathies. It is to be expected that by increasing the therapeutic armamentarium with agents that have different mechanisms of action even challenging cases could be successfully managed, thus reducing disease burden and disability.<\/jats:p>","DOI":"10.1177\/1759720x221100299","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T02:08:26Z","timestamp":1653444506000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["A glance into the future of myositis therapy"],"prefix":"10.1177","volume":"14","author":[{"given":"Ilaria","family":"Chiapparoli","sequence":"first","affiliation":[{"name":"Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Galluzzo","sequence":"additional","affiliation":[{"name":"Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[{"name":"Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy"},{"name":"Universit\u00e0 di Modena e Reggio Emilia, Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2002-7185","authenticated-orcid":false,"given":"Nicol\u00f2","family":"Pipitone","sequence":"additional","affiliation":[{"name":"Arcispedale Santa Maria Nuova, Viale Risorgimento 80, 42123 Reggio Emilia, Italy"},{"name":"Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,5,24]]},"reference":[{"key":"bibr1-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1491307"},{"key":"bibr2-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-020-00943-2"},{"key":"bibr3-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133702"},{"key":"bibr4-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1002\/art.37754"},{"key":"bibr5-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew146"},{"key":"bibr6-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190505"},{"key":"bibr7-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2020.0410"},{"key":"bibr8-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1080\/030097400750001897"},{"key":"bibr9-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.161217"},{"key":"bibr10-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.747335"},{"key":"bibr11-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211751"},{"key":"bibr12-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2010.02334.x"},{"key":"bibr13-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202857"},{"key":"bibr14-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2012.01.001"},{"key":"bibr15-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.11.019"},{"key":"bibr16-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205278"},{"key":"bibr17-1759720X221100299","first-page":"474","volume":"31","author":"Pipitone N","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"bibr18-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1650-8"},{"key":"bibr19-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket279"},{"key":"bibr20-1759720X221100299","first-page":"0443","volume":"1","author":"Safety and efficacy of belimumab in the treatment of adult idiopathic inflammatory myositis (polymyositis dermatomyositis)","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"bibr21-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1002\/art.40049"},{"key":"bibr22-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-13-8871-2_20"},{"key":"bibr23-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.01.021"},{"key":"bibr24-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key366"},{"key":"bibr25-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14939"},{"key":"bibr26-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1002\/art.41602"},{"key":"bibr27-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key188"},{"key":"bibr28-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab421"},{"key":"bibr29-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa377"},{"key":"bibr30-1759720X221100299","doi-asserted-by":"crossref","first-page":"e050004","DOI":"10.1136\/bmjopen-2021-050004","volume":"11","author":"Wu W","year":"2021","journal-title":"BMJ Open"},{"key":"bibr31-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1038\/srep33226"},{"key":"bibr32-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205681"},{"key":"bibr33-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.07.006"},{"key":"bibr34-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126452"},{"key":"bibr35-1759720X221100299","first-page":"958","volume":"72","author":"Aggarwal R","year":"202","journal-title":"Arthritis Rheumatol"},{"key":"bibr36-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-23539-4"},{"key":"bibr37-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez020"},{"key":"bibr38-1759720X221100299","volume":"72","author":"Del Rio Oliva M","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"bibr39-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1124\/molpharm.120.000083"},{"key":"bibr40-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215396"},{"key":"bibr41-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1186\/ar2885"},{"key":"bibr42-1759720X221100299","first-page":"1802","volume":"33","author":"Iannone F","year":"2006","journal-title":"J Rheumatol"},{"key":"bibr43-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202794"},{"key":"bibr44-1759720X221100299","first-page":"S403","volume":"910","author":"Danko K","year":"2014","journal-title":"Arthritis Rheum"},{"key":"bibr45-1759720X221100299","volume":"9","author":"A double-blind, placebo-controlled, phase 2 trial of a novel toll-like receptor 7\/8\/9 antagonist (IMO-8400) in dermatomyositis","year":"2021","journal-title":"Ann Transl Med"},{"key":"bibr46-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1897567"},{"key":"bibr47-1759720X221100299","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-00515-9"}],"container-title":["Therapeutic Advances in Musculoskeletal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X221100299","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1759720X221100299","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X221100299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:38:32Z","timestamp":1777588712000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1759720X221100299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":47,"alternative-id":["10.1177\/1759720X221100299"],"URL":"https:\/\/doi.org\/10.1177\/1759720x221100299","relation":{},"ISSN":["1759-720X","1759-7218"],"issn-type":[{"value":"1759-720X","type":"print"},{"value":"1759-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"1759720X221100299"}}